Downloads: 624

Files in This Item:
File Description SizeFormat 
17_429.pdf745.08 kBAdobe PDFView/Open
Title: 尿路感染症に対するRifampicinの臨床効果について
Other Titles: Clinical evaluation of rifampicin for urinary tract infection
Authors: 小林, 啓躬  KAKEN_name
高橋, 陽一  KAKEN_name
沢西, 謙次  KAKEN_name
友吉, 唯夫  KAKEN_name
松尾, 光雄  KAKEN_name
高山, 秀則  KAKEN_name
土屋, 正孝  KAKEN_name
中川, 清秀  KAKEN_name
岡田, 謙一郎  KAKEN_name
久世, 益治  KAKEN_name
上山, 秀磨  KAKEN_name
伊東, 三喜雄  KAKEN_name
Author's alias: KOBAYASHI, Hiromi
TAKAHASHI, Yoichi
SAWANISHI, Kenji
TOMOYOSHI, Tadao
MATSUO, Mitsuo
TAKAYAMA, Hidenori
TSUCHIYA, Masataka
NAKAGAWA, Kiyohide
OKADA, Kenichiro
KUZE, Masuji
UEYAMA, Hidemaro
ITOH, Mikio
Keywords: Administration, Oral
Adolescent
Adult
Aged
Ampicillin/therapeutic use
Clinical Trials as Topic
Cystitis/drug therapy
Female
Humans
Kidney Failure, Chronic/blood
Male
Microbial Sensitivity Tests
Middle Aged
Prostatitis/drug therapy
Pyelonephritis/drug therapy
Rifampin/administration & dosage/blood/therapeutic use
Urethritis/drug therapy
Urinary Tract Infections/drug therapy/microbiology
Issue Date: Jun-1971
Publisher: 京都大学医学部泌尿器科学教室
Journal title: 泌尿器科紀要
Volume: 17
Issue: 6
Start page: 429
End page: 442
Abstract: Clinical evaluation of rifampicin for urinary tract infection was made by means of a double blind method with aminobenzylpenicillin as a control drug. The following results were obtained. Rifampicin was administered to 72 cases and aminobenzylpenicillin to 67 cases. Clinical effects of both were comparatively studied, and there was no statistical difference between both groups. Both groups were proVed to consist of similar grade of urinary tract infection as to symptOms and signs. No serious side effects were observed. From the above results, this new antibiotic, rifampicin, may be entitled to join in the battle against urinary infection.
URI: http://hdl.handle.net/2433/121267
PubMed ID: 4934923
Appears in Collections:Vol.17 No.6

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.